Furthermore, we assessed TRIB3 expression in recurrent HCC patients who had undergone sorafenib therapy prior to secondary resection, revealing a marked elevation of TRIB3 in recurrent tumor tissues compared to matched primary resected samples (Figure 1B, n = 15, p < 0.001). Here, TRIB3 is linked to hepatocellular carcinoma.